Hyperfine Inc (HYPR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.75+8.36%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · HYPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -17.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 52.0% |
Growth built into the price is above our model estimate.
The price assumes 69.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
HYPR — earnings in line
Dated 2026-10-08
Results of Operations and Financial Condition. On October 8, 2026, Hyperfine, Inc. (the “Company”) issued a press release and updated its corporate presentation (the “Investor Presentation”), as described further below, each of which included information with respect to certain preliminary unaudited financial results of the Company. For the quarter ended September 30, 2026, the Company had estimated total revenue of approximately $6.0 million, for the nine months ended September 30, 2026, the…
Why it matters: Q3 revenue was preliminary at about $6.0 million. The Nov. 9 report will show if results support the $20–$22 million yearly goal.
Watch forFinal Q3 revenue is about $6.0 million or more. Management keeps its 2026 revenue outlook at $20–$22 million.
Also watch forFinal Q3 revenue is below $6.0 million. Or management cuts its 2026 revenue outlook to below $20 million.
Why it matters: System sales and scan use give a direct read on demand across care sites. Q2 system sales rose 50% year over year.
Supportive ifA later quarter reports more than 12 Swoop systems sold, above Q2's 12 systems.
Worry ifA later quarter reports fewer than 12 Swoop systems sold, or reports falling scan volume across U.S. sites.
Why it matters: Cash burn has improved, but nine-month burn was already about $22.2 million. The full-year result will test the $26–$28 million goal.
Worry ifReported 2026 net cash burn, not counting financing, is above $28 million.
Less concerning ifReported 2026 net cash burn is $28 million or less, within management's stated range.
Why it matters: Hyperfine has cleared Swoop for Europe and started sales there, while a system is in clinical use in India. Reported sales can test this expansion.
Supportive ifA company update reports new paid Swoop system sales in Europe or India. These go beyond the first sales and first India system.
Worry ifA later update reports no further paid sales in these markets, or says a launch has been paused.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$234 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $696 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,297 loss on $10,000 · 63.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Nasdaq sent a notice after HYPR's stock closed below $1 for 30 straight business days. A listing update will resolve this risk.
Watch forNasdaq confirms HYPR has regained compliance with its $1 bid-price rule or grants a compliance extension.
Also watch forNasdaq decides to delist HYPR, or HYPR does not meet the stated compliance terms by the deadline.